Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 11/2020

01-11-2020 | Multiple Sclerosis | Original Article

A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting

Authors: R. Lanzillo, M. Sparaco, L. Lavorgna, L. Carmisciano, E. Signoriello, A. Signori, T. Costabile, G. T. Maniscalco, F. Saccà, S. Cepparulo, C. V. Russo, A. Bisecco, N. Frattaruolo, A. Strianese, G. Lus, V. Brescia Morra, S. Bonavita

Published in: Neurological Sciences | Issue 11/2020

Login to get access

Abstract

Background

Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS).

Objective

To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS).

Methods

Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group.

Results

Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM.

Conclusions

Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results.
Appendix
Available only for authorised users
Literature
1.
Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, la Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP, iMUST group. (2017) Assessing association of comorbidities with treatment choice and persistence in MS: a real-life multicenter study. Neurology 89: 2222–2229
2.
D’Amico E, Leone C, Caserta C et al (2015) Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother 15:803–824CrossRef
3.
Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C, R.I.Re.MS study group. (2018) R.I.Re.MS study group. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. J Neurol 265(5):1174–1183
4.
Havrdova E, Galetta S, Stefoski D et al (2010) Freedom from disease activity in multiple sclerosis. Neurology 74(Suppl. 3):S3–S7CrossRef
5.
US Department of Health and Human Services Food and Drug Administration, FDA (2009). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims
6.
Speight J, Barendse SM (2010) FDA guidance on patient reported outcomes. BMJ 340:c292CrossRef
7.
Giovannoni G, Tomic D, Bright JR et al (2017) “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179–1187CrossRef
8.
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483CrossRef
9.
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ (2009) The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler 15(9):1092–1102CrossRef
10.
Atkinson MJ, Sinha A, Hass SL et al (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12CrossRef
11.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRef
12.
Beck AT, Steer RA, Brown GA (1996) Beck Depression Inventory-II (BDI-II) manual. Pearson, Oxford, England
13.
Learmonth YC, Motl RW, Sandroff BM et al (2013) Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 13:37CrossRef
14.
Lavorgna L, Sparaco M, Esposito S, Motl RW, Gallo A, Bisecco A, Tedeschi G, Bonavita S (2017) Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis. Mult Scler Relat Disord 18:173–176CrossRef
15.
Lavorgna L, Miele G, Petruzzo M, Lanzillo R, Bonavita S (2018) Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis. Mult Scler Relat Disord. 21:108–109CrossRef
16.
Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol 14(2):75–93CrossRef
17.
Benedict, R.H., DeLuca, J., Phillips, G., LaRocca N., Hudson L.D., Rudick R., Multiple Sclerosis Outcome Assessments Consortium. (2017) Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 23(5): 721–733
18.
Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L (2014) Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther 36(12):1958–1971CrossRef
19.
Saccà F, Lanzillo R, Signori A, et al. (2018) On behalf of the iMUST group. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: a real-life study. Mult Scler 1352458518790390
20.
Coyle PK, Khatri B, Edwards KR et al (2018) Teri-PRO trial group. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 26:211–218CrossRef
21.
Apolone G, Mosconi P (1998) The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51(11):1025–1036CrossRef
22.
Condé S, Moisset X, Pereira B, Zuel M, Colamarino R, Maillet-Vioud M, Lauxerois M, Taithe F, Clavelou P, Réseau NeuroSEP Auvergne. (2018) Dimethyl-fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study. Eur J Neurol 26(3):460–467
Metadata
Title
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting
Authors
R. Lanzillo
M. Sparaco
L. Lavorgna
L. Carmisciano
E. Signoriello
A. Signori
T. Costabile
G. T. Maniscalco
F. Saccà
S. Cepparulo
C. V. Russo
A. Bisecco
N. Frattaruolo
A. Strianese
G. Lus
V. Brescia Morra
S. Bonavita
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 11/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04367-9

Other articles of this Issue 11/2020

Neurological Sciences 11/2020 Go to the issue

Letter to the Editor

Levodopa-carbidopa intestinal gel is an option in Parkinson’s disease with hyponatremia induced by dopamine agonists

Original Article

Muscle echo intensity of abdominal wall in Parkinson’s disease and healthy controls: a cross sectional study

Correction

Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)

Brief Communication

Intracerebral large artery disease in Aicardi-Goutières syndrome with TREX1 mutation: a case report

COVID-19

Headache and pleocytosis in CSF associated with COVID-19: case report

Original Article

Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study